Navigation Links
Medication duloxetine helps reduce pain from chemotherapy

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April 3 issue of JAMA.

"Approximately 20 percent to 40 percent of patients with cancer who receive neurotoxic chemotherapy (e.g., taxanes, platinums, vinca alkaloids, bortezomib) will develop painful chemotherapy-induced peripheral neuropathy. Painful chemotherapy-induced neuropathy can persist from months to years beyond chemotherapy completion, causing significant challenges for cancer survivors due to its negative influence on function and quality of life. Chemotherapy-induced peripheral neuropathy is difficult to manage, and most randomized controlled trials testing a variety of drugs with diverse mechanisms of action revealed no effective treatment," according to background information in the article.

There is evidence that serotonin and norepinephrine dual reuptake inhibitors are effective in treating neuropathy-related pain. Several phase 3 studies have shown that duloxetine is an effective treatment for painful diabetic neuropathy.

Ellen M. Lavoie Smith, Ph.D., of the University of Michigan School of Nursing, Ann Arbor, and colleagues conducted a randomized phase 3 trial to examine whether duloxetine would lessen chemotherapy-induced peripheral neuropathic pain. The study included 231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011. Study follow-up was completed July 2012. Stratified by chemotherapeutic drug and comorbid pain risk, patients were randomized to receive either duloxetine followed by placebo or placebo followed by duloxetine. Eligibility required that patients have a pain score of at least 4 on a scale of 0 to 10, representing average chemotherapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment.

The initial treatment consisted of taking 1 capsule daily of either 30 mg of duloxetine or placebo for the first week and 2 capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks.

The researchers found that at the end of the initial treatment period, patients in the duloxetine-first group reported a larger decrease in average pain (average change score, 1.06) than those in the placebo-first group (average change score 0.34). The observed average difference in the average pain score between the duloxetine-first and placebo-first groups was 0.73. Of the patients treated with duloxetine first, 59 percent reported any decrease in pain vs. 38 percent of patients treated with placebo first. Thirty percent of duloxetine-treated patients reported no change in pain and 10 percent reported increased pain.

The authors note that the results suggested that patients who received platinums (oxaliplatin) may have experienced more benefit from duloxetine than those who received taxanes.

Pain-related quality-of-life improved to a greater degree for those treated with duloxetine during the initial treatment than for those treated with placebo.

"In conclusion, 5 weeks of duloxetine treatment was associated with a statistically and clinically significant improvement in pain compared with placebo. Exploratory analyses raise the possibility that duloxetine may work better for oxaliplatin-induced rather than taxane-induced painful chemotherapy-induced peripheral neuropathy," the researchers write.


Contact: Nicole Fawcett
The JAMA Network Journals

Related medicine news :

1. Medication with New Herbal Formula for Fallopian Tube Conditions Now Available Online
2. Parents Will Push for Medication, Even If Doc Says Not Needed
3. UCLA study finds heart failure medications highly cost-effective
4. Diet Can Lower Blood Pressure As Much As Taking A Medication, From The March 2013 Harvard Men's Health Watch
5. SiliconMesa Partners with DrFirst to Add E-prescribing and Medication Adherence Functionality to SiliconMesa EHR
6. Know Whats in Your Childs Medications, FDA Warns
7. Certain Diabetes Medications May Lower Heart Failure Risk
8. Study: Diabetic medication may protect patients from developing heart failure
9. Study: Electronic Prescribing Cuts Medication Errors
10. Cost of medication and stigma leading asthma sufferers to risk health
11. Medication Management Company Releases Compact Dispenser
Post Your Comments:
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology: